1. Home
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Tau protein inhibitors - Pipeline Insight, 2022

Tau protein inhibitors - Pipeline Insight, 2022

  • January 2022
  • 60 pages
  • ID: 6222487
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

“Tau protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Tau protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Tau protein inhibitors Understanding

Tau protein inhibitors: Overview
Tau proteins are proteins that perform the function of stabilizing microtubules. These proteins are abundant in nerve cells and are present to a much lesser degree in oligodendrocytes and astrocytes. When Tau proteins become defective and fail to adequately stabilize microtubules, pathologies of the nervous system can develop such as Alzheimer’s disease.

Function - Tau proteins are mainly active in the distal portions of axons where they stabilize microtubules as well as providing flexibility. The proteins work together with a globular protein called tubulin to stabilize microtubules and aid the assembly of tubulin in the microtubules. Tau proteins achieve their control of microtubule stability through isoforms and phosphorylation. Hyperphosphorylation of tau proteins can cause the helical and straight filaments to tangle (referred to as neurofibrillary tangles). These tangles contribute to the pathology of Alzheimer’s disease.

Tau protein inhibitors - Alzheimer disease is characterized by pathological aggregation of two proteins, tau and A?-amyloid, both of which are considered to be toxic to neurons. Recent advances have shown small molecule inhibitors of protein aggregation with emphasis on tau, with activities mediated by the direct interference of self-assembly. The inhibitors can be clustered in several compound classes according to their chemical structure, with subsequent description of the structure–activity relationships, showing that hydrophobic interactions are prevailing.

Tau protein inhibitors Emerging Drugs Chapters
This segment of the Tau protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tau protein inhibitors Emerging Drugs
• R-phenserine: Annovis Bio
R-enantiomer (positive isomer) of phenserine, being developed by Annovis Bio (formerly QR Pharma), under a licence from Horizon Therapeutics plc (formerly Horizon Pharma), for the treatment of Alzheimer’s disease (AD) and dementia in Down syndrome (AD-DS), Parkinson’s disease (PD), stroke and traumatic brain injuries. Currently, it is in phase 2 of development stage for the treatment of Mild cognitive impairment.

• Bepranemab: UCB
Bepranemab (also known as UCB 0107) is a recombinant, humanised, full length IgG4 monoclonal antibody targeting a central tau epitope, being developed by UCB pharma for the treatment of Alzheimer’s disease; Progressive supranuclear palsy. Currently, it is in phase 1 stage of development.

• Hydromethylthionine mesylate (TRx-0237): TauRx Pharmaceuticals
Hydromethylthionine mesylate (TRx 0237) is an orally available, second-generation inhibitor of tau protein aggregation and TDP-43 aggregation being developed by TauRx Pharmaceuticals and is currently in phase 3 stage of development for the treatment of Alzheimer’s disease and Dementia.

Further product details are provided in the report……..

Tau protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Tau protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Tau protein inhibitors
There are approx. 15+ key companies which are developing the Tau protein inhibitors. The companies which have their Tau protein inhibitors drug candidates in the most advanced stage, i.e. phase III include, TauRx Pharmaceuticals.

• Phases
This report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Tau protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tau protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tau protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tau protein inhibitors drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Tau protein inhibitors R&D. The therapies under development are focused on novel approaches for Tau protein inhibitors.

Tau protein inhibitors Report Insights
• Tau protein inhibitors Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tau protein inhibitors Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Tau protein inhibitors drugs?
• How many Tau protein inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Tau protein inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tau protein inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tau protein inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Annovis Bio
• UCB Biopharma
• TauRx Pharmaceuticals
• Voyager Therapeutics
• Oligomerix
• APRINOIA Therapeutics
• Sangamo Therapeutics
• AC Immune
• Eli Lilly and Company
• Denali Therapeutics Inc
• Takeda
• TAU BIO-LOGIC
• VITRUVIAN BioMedical
• BeyondBio
• DTx Pharma
• Eisai Co Ltd
• reMYND
• Dong-A ST

Key Products
• R-phenserine
• Bepranemab
• Hydromethylthionine mesylate (TRx-0237)
• Vectorized tau antibodies
• ST 501
• ACI 3024
• AT 8 antibody
• ATV:BACE1/Tau
• TBL 100
• YM 7555
• BEY-2153
• MSUT2 programme
• E 2814
• ReS19 T
• NB 02

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Neuroprotection Market Research Report by Product, Treatment, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • $ 3949
  • October 2022
  • 241 pages

Neuroprotection Market Research Report by Product, Treatment, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 The Global Neuroprotection Market size was estimated at USD ...

  • World
  • Dementia
  • Therapy
  • Industry analysis

ref:plp2021

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on